Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

BioPharma« Terug naar discussie overzicht

INSM - Insmed - Deel 16

1.439 Posts
Pagina: «« 1 ... 6 7 8 9 10 ... 72 »» | Laatste | Omlaag ↓
  1. [verwijderd] 18 maart 2008 21:40
    Insmed Announces Additional Information in Compliance With NASDAQ Rules

    RICHMOND, Va., March 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pursuant to NASDAQ Marketplace Rule 4350(b)(1)(B) (the "NASDAQ Rule") any Company whose securities are listed on one of the NASDAQ stock exchanges that receives a going concern audit opinion in one of its filings with the Securities and Exchange Commission is required to disseminate this information to the public. In compliance with this NASDAQ Rule, Insmed Incorporated (Nasdaq: INSM), today announced that it has received a going concern audit opinion for its financial statements dated as of December 31, 2007, and filed as part of its Annual Report on Form 10-K with the Securities and Exchange Commission. This going concern audit opinion was given because the Company's ability to continue as a going concern is dependent upon its ability to raise capital through securities offerings, debt financing and partnership agreements to fund on-going operations.
  2. [verwijderd] 19 maart 2008 12:25
    IVMBRD on fob legislation

    FOB Legislation...Latest from House of Rep Eshoo...Exclusivity
    Based on READING the proposed bipartisan legislation, the exclusivity issue is very similar to the Senate legislation proposed and passed out of committee last year.

    In a nutshell. The Eshoo/Barton bill proposes 12 years data exclusivity from FDA license date (pg 10 7-A) with provisions of additional 2 years if innovator meets certain requirements (pg 12 7-D). Further, an additional 6 months if the innovator meets a pediatric clause (pg 12 8-A).

    The heading and subsequent "outrage" by the generic industry is misleading. In practical terms, the innovator does NOT get up to an additional 14.5 years after patent expiration. The bill provides for up to a maximum 14.5 years exclusivity from FDA approval/market date.

    Waxman and others proposed legislation (which is still active) a year ago provides no additional time relating to exclusivity beyond original patent protection. Bottom line, it will be a battle when the debate resumes and imo a compromise will be reached.

    What we don't know is the impact exclusivity will have on an FOB partnership. On the surface anything 12 years and under would not have an impact on Insmed's initial portfolio based on the blocking patent dates provided by Insmed and the market dates.

    I have posted this before but as a reminder, Insmed's initial FOB portfolio:
    Neupogen Market date 1998 Blocking Patent Date 2013
    Neulasta Market date 2002 Blocking Patent Date 2015
    Betaseron Market date 1993 Blocking Patent Date 2012
    Epogen Market date 1999 Blocking Patent Date 2015
    Avonex Market date 1996 Blocking Patent Date 2008

    --------------------------

    buy add, hold

    er is binnenkort geen geld nodig en vroeger of later dit jaar komt die fob partner, zo simpel is het hier los van de emotie over huidige market cap

    short term strong buy onder 0,67 , buy onder 0,80
  3. ludwig mack 19 maart 2008 19:05
    Last Trade: 0.62
    Trade Time: 1:48PM ET
    Change: 0.04 (6.06%)
    Prev Close: 0.66
    Open: 0.65
    Bid: 0.62 x 600
    Ask: 0.63 x 500
    1y Target Est: 2.00
    Day's Range: 0.57 - 0.65
    52wk Range: 0.56 - 1.22
    Volume: 441,784
    Avg Vol (3m): 448,574
    Market Cap: 75.58M
    P/E (ttm): N/A
    EPS (ttm): -0.17
    Div & Yield: N/A (N/A)
  4. [verwijderd] 20 maart 2008 13:32
    quote:

    DoDD666 schreef:

    Mensen,

    Heb m'n positie in INSM (samen met de rest van m'n US portfolio) voorlopig geliquideerd vanwege de voortdurende ellende op de US beurzen.
    INSM is echter niet uit mijn blikveld verdwenen. Ik stap weer in zodra een evt emissie achter de rug is.

    mvg, E.
    Mail me eens,
    ik verwacht niet dat die er komt
  5. junkbond 20 maart 2008 17:55
    quote:

    DoDD666 schreef:

    Mensen,

    Heb m'n positie in INSM (samen met de rest van m'n US portfolio) voorlopig geliquideerd vanwege de voortdurende ellende op de US beurzen.
    INSM is echter niet uit mijn blikveld verdwenen. Ik stap weer in zodra een evt emissie achter de rug is.

    mvg, E.
    Spijtig DoDD666, maar vooral moedig..
1.439 Posts
Pagina: «« 1 ... 6 7 8 9 10 ... 72 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.